Oramed Pharmaceuticals (ORMP) Accumulated Expenses (2018 - 2026)

Oramed Pharmaceuticals has reported Accumulated Expenses for 9 years, with the latest figure at $475000.0 in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 166.85% year-over-year to $475000.0; the trailing twelve-month figure through Mar 2026 stood at $475000.0 (up 166.85% YoY), and the FY2025 full-year result was $755000.0, up 85.5% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $475000.0, down from $755000.0 in the prior quarter.
• The five-year high for Accumulated Expenses was $841000.0 in Q2 2025, with the low at $21000.0 in Q4 2022.
• Historically, Accumulated Expenses has averaged $296615.4 across 5 years, with a median of $178000.0 in 2025.
• Annual changes were most pronounced in 2024 — Accumulated Expenses retreated 10.15% — and 2025, when it jumped 2800.0%.
• Oramed Pharmaceuticals' Accumulated Expenses stood at $21000.0 in 2022, then surged by 2057.14% to $453000.0 in 2023, then slipped by 10.15% to $407000.0 in 2024, then soared by 85.5% to $755000.0 in 2025, then tumbled by 37.09% to $475000.0 in 2026.
• The last three Accumulated Expenses figures came in at $475000.0 (Q1 2026), $755000.0 (Q4 2025), and $585000.0 (Q3 2025), per Business Quant data.